NOVARTIS AG
NVSNYSE
$153.76
↑ +0.7%Jul 17 close · end-of-day
Price
1Y↑ +33.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Novartis AG researches, develops, manufactures, and markets healthcare products. The company operates through two segments, Innovative Medicines and Sandoz. Sandoz provides finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals.
- CEO
- Vasant Narasimhan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 101,700
- Website
- novartis.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 20, 2026
- 6h agoNovartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks?finance.yahoo.com
- 11h agoNovartis pipeline faces critical test as upcoming trial results underpin growth outlookinvestorshub.advfn.com
- 12h agoBristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerbiopharmadive.com
Jul 17, 2026
- 3d agoNovartis (SWX:NOVN) Wins Fabhalta Approval, Is The Stock Already Fully Valued?finance.yahoo.com
- 3d agoCan Novartis' Fabhalta Strengthen Its Nephrology Franchise?finance.yahoo.com
- 3d agoNovartis (SWX:NOVN) Stock Looks Below Fair Value Despite An 88% Runfinance.yahoo.com
- 3d agoMRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pillfinance.yahoo.com
- 3d agoNovartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Usefinance.yahoo.com
Jul 16, 2026
- 3d agoNovartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgANfinance.yahoo.com
- 4d agoWhy Abbott Stock Is Having Its Best Day in 24 Yearsfinance.yahoo.com
- 4d agoEuropean Equities Traded in the US as American Depositary Receipts Edge Lower Thursdayfinance.yahoo.com
- 4d agoGear Up for Novartis (NVS) Q2 Earnings: Wall Street Estimates for Key Metricsfinance.yahoo.com
- 4d agoWhy Abbott Earnings Are Sending the Stock Higherfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.